AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02603575 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: caspofungin
Description: 70mg ivdrip the first day, then 50mg ivdrip qd
Study NCT02603575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: corticosteroids
Description: 40mg ivdrip q12h for 5 days 40mg ivdrip qd for 5 days 20mg po for 11 days
Study NCT02603575 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: corticosteroids
Description: 40mg ivdrip q12h for 5 days 40mg ivdrip qd for 5 days 20mg po for 11 days
Study NCT00974454 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fuzheng 2
Description: Immunity 2 (Fuzheng 2), 6.25g twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
Study NCT02603575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfanilamides
Description: 1.92g q8h
Study NCT02533973 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xamiol® gel
Study NCT02533973 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daivonex® scalp solution
Study NCT02485522 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: No intervention
Study NCT03187522 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TREO Stent-Graft System
Description: The TREO® Stent-Graft is designed for use in the management of patients with AAAs and is composed of self-expanding nitinol stents sutured to polyester vascular graft fabric.
Study NCT01471886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac Tromethamine
Description: Every 8 hours for 4 days.
Study NCT01471886 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: Every 8 hours for 4 days.
Study NCT01072890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus, Pazopanib
Description: Patients will be treated on an outpatient basis with both temsirolimus and pazopanib. All patients will receive temsirolimus intravenously (IV) weekly days 1, 8, 15, and 22. Patients will receive oral pazopanib on a daily basis starting day 1. Treatment will be administered on 28 day cycles. Patients will be in this study for a minimum of 8 weeks or 2 cycles.
Study NCT00974454 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, 6.25g twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
Study NCT03354377 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary Intervention Meetings
Description: Participants will attend classes once per week for the first 6 months, bi-weekly for the next 6 months; then once a month for the last 12 months.
Study NCT03354377 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: Participants will be given the following exercise recommendations: strength training twice per week and ≥75 min of vigorous or ≥150 min of moderate PA per week and will be provided with accelerometers.
Study NCT03354377 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Podcasts/Mailings
Description: Participants with receive additional support delivered remotely months 13-24 in the form of audio podcasts and email newsletters.
Study NCT02603575 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfanilamides
Description: 1.92g q8h
Study NCT03222492 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo control for blinding (masking), 0.95% normal saline.
Study NCT02128360 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole, Gonadotropins
Study NCT02734147 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ascorbic Acid
Study NCT02734147 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Study NCT02128360 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gonadotropins
Study NCT03865576 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Non-invasive ICP measurement
Description: Intracranial pressure will be measured non-invasively using transorbital Doppler ultrasound. Values will be compared to ICP measured by lumbar puncture or implanted ICP sensors
Study NCT02280954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green (ICG)
Study NCT00617643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine without dose escalation
Description: Fixed dose combination tablets of stavudine 30mg,lamivudine 150mg and nevirapine tablets 200mg twice daily at initiation of antiretroviral therapy in patients receiving rifampicin for tuberculosis therapy
Study NCT00617643 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nevirapine initiation with dose escalation
Description: Triomune® 30 (according to body weight) one tablet once daily (am) plus Zerit® 30 + Epivir 150mg once daily (pm) for two weeks
Study NCT03080077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ricrolin+
Description: The IONTOPHOR CXL iontophoresis applicator and the associated blepharostat will be placed onto the cornea to be treated. The applicator will be secured to the cornea and filled with Ricrolin+ which as been aspirated from the bottle using a syringe with a needle. The generator will be switched on and set to 1 mA for 5 minutes. The generator will then be disconnected and the applicator will be removed from the cornea.
Study NCT03080077 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epi-Off
Description: Using topical anesthesia (proparacaine), the surgeon will create a complete corneal abrasion to facilitate riboflavin diffusion into the cornea. The epithelium will be removed by gently brushing the cornea with a scalpel. A corneal abrasion diameter of \~9mm is recommended, which may be adjusted as needed at the discretion of the investigator to accommodate individual eye geometry. Ultrasound corneal pachymetry should be performed before dis-epithelialization and after dis- epithelialization. Local anesthetics will be administered as needed to maintain patient comfort during the CXL procedure.
Study NCT00235001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trandolapril/verapamil
Description: 180/2 mg QD
Study NCT02656212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epicatechin
Description: 30 mg (+)-epicatechin, taken orally, one pill/day in the morning
Study NCT02656212 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pill, taken orally, one pill/day in the morning
Study NCT02025556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBR-101 High Dose
Description: Subcutaneously Administered High Dose LBR-101 Monthly x 3
Study NCT02025556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBR-101 Low Dose
Description: Subcutaneously Administered Low Dose LBR-101 Monthly x 3
Study NCT02025556 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneously Administered Placebo (Vehicle) Monthly x 3
Study NCT03778372 — intervention group
Intervention type: DRUG
Intervention: Methadone
Description: see desc above
Study NCT04573959 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SV-3 Capsule Endoscopy
Description: The purpose of this study is to validate an updated version of the CapsoCam SV-3 Endoscopy System with respect to the reproducibility of the system to capture and download small bowel images in a manner consistent with the predicate CapsoCam SV-3 capsule endoscopy.
Study NCT01172314 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: EAA+LEU vs total AA
Description: 15 g as a bolus
Study NCT01172314 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Total AA vs EAA+LEU
Description: 15 g as a bolus
Study NCT03466554 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen-90 minutes exposure to 100% oxygen at 2 ATA, with 5-minute air breaks every 20 minutes
Description: 60 daily HBOT sessions will be administrated 5 days per week. comprise of 90 minutes exposure to 100% oxygen at 2 ATA, with 5-minute air breaks every 20 minutes.
Study NCT02112045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granix
Study NCT02112045 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High dose melphalan (HDR)
Study NCT02112045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose melphalan (HDR)
Study NCT01477450 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pulse-dose oxygen
Description: Pulsed-dose oxygen delivery from an oxygen concentrator
Study NCT01477450 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cylinder oxygen delivery
Description: Oxygen delivery from an oxygen cylinder
Study NCT02112045 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autologous Stem Cell Transplant (ASCT)
Study NCT02112045 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Stem Cell Transplant (ASCT)
Study NCT03681288 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Self-Compassion
Description: Mindful Self-Compassion Intervention
Study NCT01960907 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CHROMED monitoring system
Description: Optimization of patient's treatment according to the data collected by the home monitoring devices
Study NCT03526874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine 4% Topical Application Cream [LMX 4]
Description: Run-in Step: All subjects receive 32 mg (4 cm ribbon of cream) applied, bilaterally, over greater occipital nerve.
Study NCT03526874 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lidocaine 4% Topical Application Cream [LMX 4]
Description: Run-in Step: All subjects receive 32 mg (4 cm ribbon of cream) applied, bilaterally, over greater occipital nerve.
Study NCT03526874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Hydrochloride 2 mg/mL Injectable Solution
Description: Subjects, who continue to experience headache pain after the run-in step, receive 2 (2 mL) injections of the active treatment.
Study NCT03526874 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Subjects, who continue to experience headache pain after the run-in step, receive 2 (2 mL) injections of the comparator.
Study NCT03086967 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Double-lumen balloon catheter
Description: introduction of catheter into cervix for ripening prior to induction of labor following standard of care practices
Study NCT01955486 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flight simulation
Study NCT00988390 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive-behavioral, small-group format sessions
Description: The intervention was delivered in either English- or Spanish-speaking groups of 5 to 8 mothers living with HIV twice weekly for 1.5 to 2 hours each over eight weeks (n = 16 sessions).
Study NCT00914212 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose placebo to sibutramine in two of three treatment periods.
Study NCT00914212 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: sibutramine
Description: Single dose sibutramine 30 mg (2 x 15 mg) in one of three treatment periods.
Study NCT04426656 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone application
Description: The mini-app (used in Part 2) has four main functions:~1. a knowledge center that contains a series of HIV-, sexual health-, and PrEP-related educational articles in Chinese;~2. an HIV self-test toolkit ordering system that allows users to order a finger-prick HIV rapid test toolkit and shipped to home for free (one piece at a time);~3. an asynchronous message function that allows users to chat with a study staff (C.Li); and~4. a user profile page where users can manage all HIV test orders.
Study NCT05737147 — intervention group
Intervention type: DEVICE
Intervention: Zero Heat Flux Thermometer
Description: Comparison of the accuracy and precision of a Zero Heat Flux Thermometer (SpotOn) Versus Pulmonary Artery Temperature Measurement
Study NCT00627445 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: biphasic insulin aspart 30
Description: Treat-to-target dose titration scheme (dose adjusted individually), s.c. (under the skin) injection before dinner
Study NCT00627445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 30
Description: Treat-to-target dose titration scheme (dose adjusted individually), s.c. (under the skin) injection before dinner
Study NCT00627445 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: Tablets, 500 - 2000 mg, once, twice or three times daily
Study NCT00627445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: Tablets, 500 - 2000 mg, once, twice or three times daily
Study NCT00627445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 50
Description: Treat-to-target dose titration scheme (dose adjusted individually), s.c. (under the skin) injection before breakfast and lunch
Study NCT04505540 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bridge Clinic
Description: Specialized addiction bridge clinic
Study NCT01722227 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Study NCT01722227 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04136119 — intervention group
Intervention type: OTHER
Intervention: questionnaire
Description: survey exploring practice of vitamin and micronutrient supplementation
Study NCT03959319 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Movement Pattern Training
Description: Treatment will include 10 supervised sessions over 12 weeks and instruction in a home exercise program After randomization, participants will be scheduled with a physical therapist trained in standard procedures. Treatment will include assessment of patient goals, patient education and instruction in a home program. Patient education will focus on patient-specific tasks, identified by the participant to be symptom-producing.
Study NCT03959319 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual Therapy
Description: Treatment will include 10 supervised sessions over 12 weeks and instruction in a home exercise program After randomization, participants will be scheduled with a physical therapist trained in standard procedures. Treatment will include assessment of patient goals, patient education and instruction in a home program. Patient education will focus on patient-specific tasks, identified by the participant to be symptom-producing.
Study NCT01102283 — intervention group
Intervention type: DEVICE
Intervention: Evolution(R) Colonic Stent
Description: Palliative treatment of colonic obstruction or strictures caused by malignant neoplasms and to relieve acute large bowel obstruction prior to colectomy in patients with malignant strictures.
Study NCT04317027 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: New Fighting Clothing
Description: VO2max test Clothing examination- 2-hour walk in 6 kph/4% elevation under 30 degrees Celsius and 60% relative humidity
Study NCT04221243 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D printed space maintainer by NextDent Ortho Rigid
Description: Biocompatible 3D printing material
Study NCT04221243 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Band and Loop
Description: metal space maintainer
Study NCT04672252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD Oral Disintegrating Tablet (ODT)
Description: Cohort 1: CBD ODTs to be administered with routine post-operative pain management regimen
Study NCT04672252 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ODT
Description: Cohort 2 will not receive CBD; but a visually indistinguishable placebo ODT instead.~The resident physician, physician assistant, anesthesiologist, surgeon and study team members will remain blinded. Additionally, all patients will receive a traditional upper extremity interscalene block as per routine.
Study NCT00334074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine and Cytarabine
Description: Phase II Trial of Clofarabine and Cytarabine in Relapsed Standard-Risk AML and Untreated High-Risk MDS in Adult Patients, and Untreated AML in selected Elderly Patients at high risk of anthracycline toxicity
Study NCT01582854 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Actovegin
Description: Actovegin solution for infusion and Actovegin tablets
Study NCT01582854 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Actovegin placebo-matching solution for infusion and Actovegin placebo-matching tablets
Study NCT00977080 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paricalcitol
Description: Paricalcitol dosed per label by region (participants were to receive cinacalcet if they developed hypercalcemia)
Study NCT02286674 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tablet (Audio/Visual Device)
Description: Subjects will be given a tablet to use before surgery
Study NCT03952741 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Study NCT03952741 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Study NCT02242240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol once daily
Study NCT00977080 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cinacalcet
Description: On-label oral cinacalcet by region with low dose vitamin D receptor activator (VDRA) (either doxercalciferol at US sites or alfacalcidol at non-US sites)
Study NCT03964337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Cabozantinib 40 mg by mouth daily for 4 weeks.
Study NCT03964337 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Prostatectomy
Description: Radical prostatectomy as part of routine medical care.
Study NCT01015196 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zavedos
Study NCT02242240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium once daily
Study NCT01015196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cerubidine
Study NCT01253733 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MD2ME
Description: The goals of the MD2Me intervention include increasing disease self-efficacy, disease knowledge, and the ability to control one's disease independently. The intervention includes an 8-week web program with weekly behavioral skills, topics on how to navigate the healthcare system, lifestyle tips, a Discussion Board, and text messages.
Study NCT02421393 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: supervised exercise training
Description: Two weekly sessions of 75 min each, supervised by an exercise specialist in a dedicated gym facility. Each session will include: 5 min of warm up; 20 min of aerobic training using treadmill; 15 min of resistance training of muscle groups of skeletal sites of fragility fractures; 15 min of weight bearing exercises using weighted vests; 8 min of core stability training; 8 min of balance training; and 4 min of flexibility training. Weighted vest worn also during aerobic training and any occupational, home and leisure-time physical activity.
Study NCT00820430 — intervention group
Intervention type: OTHER
Intervention: Magnetic Resonance Imaging
Description: Subjects will undergo 4 sequential MRI evaluations of the target knee within a 4 week period to calculate precision error (ICC) in determination of cartilage morphometry (cartilage volume, mean thickness, and surface area), cartilage collagen (regional cartilage T2), and cartilage proteoglycan (regional cartilage T1rho).
Study NCT02242240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT00229619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab (Rituxan) 375mg/m2 intravenous infusion. The infusion will be once every week for a total of 4 doses.
Study NCT03886623 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 4-day systematic oral hygiene
Description: he intervention proposed would include a 4-5 day systematic oral hygiene program. Using a pea-sized amount of Colgate Total Clean Mint Toothpaste with a Battery-operated Oral-B Pro-Health Type 3744 toothbrush, all surfaces, tongue-side, check-side, and biting surfaces of the participants teeth will be brushed. The tongue will be brushed with a GUM Dual Action Tongue Cleaner and flossing will be done with GUM Flossmate handle and Oral B Guide Floss in between the contacts of each tooth. The mouth will then be rinsed with Crest Pro-Health mouthwash rinse for 30 seconds twice daily. A Medline Remedy Phytoplex lip balm will then be applied.
Study NCT05466903 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Early diet opening
Description: Effects of early dietary recovery after colon polypectomy and colonoscopic mucosal resection on postoperative hemorrhage in patients
Study NCT02488694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: 40 mg/d
Study NCT02488694 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: 500 mg/m² i.v. on d1 of each 21-day cycle